Evidence map›Paper›PMID 38556931›Full record

ArticleTurk psikiyatri dergisi = Turkish journal of psychiatry2024

Serum HMGB1 and Beclin 1 Levels in Patients with a Diagnosis of Schizophrenia.

Sevler Yildiz, Aslı Kazğan Kiliçaslan, Burcu Sirlier Emir, Kerim Uğur, Faruk Kiliç

Open access · diamondAbstract read
In one paragraph

Article in Turk psikiyatri dergisi = Turkish journal of psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sevler Yildiz
Aslı Kazğan Kiliçaslan
Burcu Sirlier Emir
Kerim Uğur
Faruk Kiliç

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIt is known that inflammation plays a role in the etiopathogenesis of schizophrenia. In this study, we examined high mobility group box 1 protein (HMGB1) and Beclin 1 levels and their relationship with clinical variables in patients with schizophrenia.

methodForty-three patients with schizophrenia and 43 healthy controls were included in this study. The patients were administered sociodemographic data form, the Positive Negative Symptoms Assessment Scale (PANSS) and the Clinical Global Impressions (CGI) scale. After the scales were filled, venous blood samples were taken from both the patient and control groups to measure serum HMGB1 and Beclin 1 levels. Serum samples obtained at the end of centrifugation were measured by Enzyme-Linked ImmunoSorbent Assay (ELISA) method.

resultsThe mean serum HMGB1 levels were significantly increased and the mean serum Beclin 1 levels were significantly decreased in the schizophrenia group compared to the control group. In addition, a negative correlation was found between HMGB1 and Beclin 1 levels.

conclusionIn conclusion, current research shows that HMGB1 is increased and Beclin 1 is decreased in patients with schizophrenia, and these findings may contribute to the role of autophagy in the pathogenesis of schizophrenia.

Indexed as

HMGB1 ProteinSchizophreniaBeclin-1Enzyme-Linked Immunosorbent AssayHumansInflammationBeclin-1HMGB1 ProteinBeclin 1 Autophagy.High Mobility Group Box 1Schizophrenia

Identifiers

PMID38556931
PMCPMC11003366
OpenAlexW4387623806

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.